[Fix Long Study: A Factor Ix (Fix) Gene Transfer, Multi Center Evaluation Of The Long Term Safety And Efficacy Study Of Spk 9001 (Raav Spark100 Hfix Padua) In Individuals With Hemophilia B]
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2019
At a glance
- Drugs Fidanacogene-elaparvovec (Primary)
- Indications Haemophilia B
- Focus Adverse reactions
- Acronyms FIX-LONG Study
- Sponsors Spark Therapeutics
- 11 Feb 2019 Planned End Date changed from 30 Mar 2024 to 29 Dec 2023.
- 11 Feb 2019 Planned primary completion date changed from 30 Mar 2024 to 29 Dec 2023.
- 09 Oct 2018 Planned number of patients changed from 15 to 20.